Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MRE (medco research) -- Ignore unavailable to you. Want to Upgrade?

To: Xiaoping Zhang who wrote (103)	7/6/1998 11:28:00 AM
From: Harold V	Read Replies (1) \| Respond to of 192

Scott and Xioping: Xioping, I think you've covered the basics, except to say that MRE is so confident in its pipeline that the investor protection (poison pill) action the company took a few months ago said--if I recall accurately--that the company can't be bought out for less than over $90/share. The company also estimated that the pipeline of drugs that it's confident in is worth over $3 billion. These, however, are predictive, not certain, developments. What is certain is that the uses of adenoscine are expanding, such that MRE has continued to come out with earning surprises--again, not a sure thing in the future, but certainly a sign of the efficacious uses of adenoscine. If MEDR640 is approved, the profitibility of MRE is skyrocket. Approval, of course, is always a long and tough process, but the clinical trials for the uses of Adenoscine for detecting cardiac damage and for ensuring faster healing are, thus far, impressive. MRE is active both in its sponsorship of more R&D and in its attention to buying the rights of other discovered uses of Adenoscine and its cognate formulations. I'm sure the company will send you scientific articles about Adenoscine studies, as well as its past press releases concerning its poison pill package, etc. Harold V.

To: Xiaoping Zhang who wrote (103)	7/12/1998 10:30:00 PM
From: Cacaito	Respond to of 192

Check this one: ncbi.nlm.nih.gov If one could find the full article will be better. Notice the reference to two 1997 ongoing phase II studies, which are already completed but I have not being able to track a journal or publication, but the company's news seems to be related to these two. Little information from med-line, as usual biotechs are late in publishing their research, as opposed to academicians who wants their research publish as soon as possible.